Abstract Estrogen receptor a (ERa) is highly regulated through multiple mechanisms including cell signaling, posttranslational modifications, and protein-protein interactions. We have previously identified a K303R ERa mutation within the hinge region of ERa. This mutation results in an altered posttranslational regulation and increased in vitro growth in the presence of low estrogen concentrations. We sought to determine if cells expressing this mutant ERa would display hypersensitive tumor growth in in vivo athymic ovariectomized nude mice. MCF-7 cells, stably expressing the K303R ERa, formed tumors in nude mice faster than cells expressing wild-type ERa in the presence of low levels of estrogen. When estrogen was withdrawn, all tumors regressed but half of the K303R ERa-expressing tumors became estrogen-independent and regrew. We evaluated potential mechanisms for the observed hypersensitivity. The mutant ERa did not demonstrate increased estrogen binding affinity, but did exhibit increased interactions with members of the SRC family of coactivators. The mutant ERa demonstrated increased levels and occupancy time on the pS2 promoter. In the presence of the K303R ERa, the SRC-3 and p300 coactivators also displayed increased levels and time on the pS2 promoter. The K303R ERa has, in part, lost critical negative regulation by the F domain. Collectively, these data demonstrate an important role for the K303R ERa mutation in hormonal regulation of tumor growth and estrogen-regulated promoter dynamics in human breast cancer.
Introduction
Long-term estrogen deprivation of breast cancer cells has been shown to result in adaptive hypersensitivity to low concentrations of estrogen [1] [2] [3] . When compared with wildtype MCF-7 cells, MCF-7 breast cancer cells that have undergone adaptive hypersensitivity display an increased ability to grow in nude mice under low estrogen conditions and growth can be inhibited when estrogen concentrations are increased [4] . Mutations within the ERa have also been shown to lead to estrogen hypersensitivity in vitro [5, 6] ; however, these data have not been confirmed by in vivo tumor growth like the adaptive hypersensitivity studies.
The serine at position 305 of ERa has been the subject of much interest. It is phosphorylated by a number of kinases including p21/Cdc42/Rac1-activated kinase 1 (Pak-1) and protein kinase A (PKA). While these kinases phosphorylate the same ERa residue, they do not result in identical responses. For instance, ERa phosphorylation by Pak-1 results in a concomitant increase in S118 phosphorylation [7] , whereas phosphorylation by PKA leads to a reduction in S118 phosphorylation [8] . Expression of a constitutively activated Pak-1 resulted in increased basal and estrogeninduced ERE-luciferase transactivation activity [7] , and siRNA to Pak-1 significantly suppressed estrogen-induced transcriptional activity [9] . In contrast, activation of PKA with forskolin resulted in a slight elevation of basal ERa activity, but it blunted estrogen-induced activity [8] . Thus, while Pak-1 and PKA can both phosphorylate ERa, at the S305 residue, the resulting biologic effects may be dependent upon the specific kinase.
Mutational analysis of S305 has demonstrated that this residue plays an important role in the regulation of ERa transactivation functions. It has been shown that mutating this serine to glutamic acid results in an elevated basal and estrogen-induced activity [9] . We have shown that the S305D mutation also leads to increased estrogen sensitivity [10] . Analysis of ERa target proteins have confirmed these results. Cells expressing the S305E mutation were found to express higher levels of cyclin D1 and Zinc finger-147 genes [11] . Furthermore, the cyclin D1 promoter was found to have higher activity with S305E but not with a S305A mutation [11] . Forskolin activation of PKA leads to increased phosphorylation of S305 and increased the recruitment of ERa to the pS2 and c-Myc promoters [8] . Thus, mutation of S305 to mimic the phosphorylation of serine results in a general increase in ER transactivation and estrogen sensitivity.
We have identified a K303R ERa mutation, and demonstrated that it is hypersensitive for in vitro growth to low levels of estrogen [5] . Both K303 and S305 residues lie within the hinge domain of ERa, and we have previously shown that phosphorylation of S305 can inhibit acetylation at the K303 residue [10] . Thus, these two residues probably work in concert to regulate ERa activity. While activation of PKA signaling by 8-bromo-cAMP did not increase wildtype ERa transactivation, it significantly increased transactivation by the K303R mutant ERa [10] . Additionally, this increased transactivation could be blocked by the PKA inhibitor, H89 [10] . Previous binding analyses of the K303R ERa mutant have demonstrated that more SRC-2 coactivator is bound to the mutant receptor when compared with the WT receptor [5] . Additionally, the receptor corepressor MTA-1 can suppress the activity of both wild-type and the mutant K303R ERa [12] whereas MTA-2 is only able to suppress the activity of the wild-type receptor [13] . Collectively, these data suggest a role for S305 phosphorylation and altered coregulator protein interactions in the hypersensitive phenotype of the K303R ERa mutant.
Previous studies have demonstrated that ERa cofactor cycles on and off of the promoter in a dynamic manner [14] [15] [16] . An elegant study by Reid et al. have shown that unliganded receptor cycles on and off of the pS2 promoter with a 20-30 min cycling time and when estrogen is added, the cycling time increased to 30-50 min [14] . Two additional studies have shown that a slightly longer cycling interval of 75-90 min in both the absence and the presence of estrogen [15, 16] . Similar cycling dynamics were also shown for ERa on the cathepsin D promoter [15] . Of note, in the presence of the proteosome inhibitor MG132, unliganded ERa only demonstrated one on/off cycle, and in the presence of estrogen, the ''on'' cycle time remained the same, but the ''off'' cycle time was extended to almost 60 min [14] . Additionally, it has been shown that the dynamics of AIB1 binding on the pS2 promoter paralleled those of ERa [15, 16] . Collectively, these data demonstrate that the cycling dynamics of the promoter occurs in a regulated and context-dependent manner.
Together, these data led us to study whether the K303R ERa mutation may alter post-translational regulation of the receptor, thereby influencing ERa function. In this article, we seek to determine the molecular mechanisms leading to the hypersensitive phenotype of the K303R mutant ERa using both in vivo and in vitro assays. Here, we show that cells overexpressing the K303R ERa mutation form larger tumors, when compared with WT ERa expressing cells in the presence of low estrogen concentrations. Furthermore, the K303R mutant protein displayed increased binding to additional members of the SRC family of coactivators. The K303R ERa mutant resides on the estrogen-regulated pS2 promoter for longer periods, and does not ''cycle-off'' with the same dynamics as wild-type ERa. Additionally, we demonstrate a possible role for helix 13 within the F domain of ERa receptor in the hypersensitive phenotype. Taken together, our data suggest that altered post-translational regulation of ERa leads to increased binding of coactivators and reduced binding of corepressors, thus contributing to the hypersensitive phenotype of the mutant K303R ERa.
Materials and methods

Cell culture
Breast cancer cells were maintained on plastic in minimum essential medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS), 0.1 mM nonessential amino acids, 2 mM L-Glutamine, 50 U/ml penicillin/streptomycin (Gibco), and at 37°C with 5% CO 2 -95% air. Unless otherwise noted, cells were passaged and removed from flasks when 70-80% confluent. For cell passage, cells were rinsed with PBS and trypsinized in 0.05% trypsin and 0.02% EDTA for 2 min at 37°C. Trypsin activity was quenched with the addition of medium containing 10% FBS.
Plasmid constructs
The mammalian expression vector for the full-length YFPtagged wild-type receptor (WT ERa) and an YFP-tagged K303R mutant receptor (K303R-ERa), as well as the bacterial expression vectors for glutathione-S-transferase (GST)-ERa and GST-K303R-ERa hinge-and hormonebinding domain have been previously described [10] . The mammalian expression vectors for SRC-1 [17] , TIF2/SRC-2 [18] , AIB1/SRC-3 [19] , GST-TFIIB [20] , and GST-TBP were obtained from Dr. Tsai MJ of Baylor College of Medicine, Houston, Texas.
Animal care and necropsy
Animals were housed and maintained in accordance with the animal care regulations of Baylor College of Medicine. All of the animal experiments were approved by the Baylor College of Medicine Animal Care and Use Committee pursuant to NIH guidelines. Female ovariectomized athymic nude mice purchased from Harlan Sprague-Dawley, Inc (Indianapolis, IN, USA), maintained under specific pathogen-free conditions, and used for experiments at 5-6 weeks of age. Animals were killed and necropsied when tumor burden was 1 cm 3 or when animals were moribund. All procedures were performed, while the animals were anesthetized with isoflurane (Abbot Laboratories, North Chicago, IL, USA).
Tumor cell implantation
Cells expressing the wild-type or mutant ERa's are described elsewhere [21] . Briefly, MCF-7 cells were engineered to overexpress YFP-WT ERa and YFP-K303R-ERa plasmids, and demonstrate similar levels of ERa expression [10] . Cells grown in T150 flasks were given fresh media free of eukaryotic antibiotics 2 days prior to injection of cells. Cells in the log phase of growth, we rinsed once with PBS, removed from the flask with 5 ml of Versene (Gibco), and collected with 10 ml of growth media. Cells were collected by centrifuging for 7 min at 1,200 rpm. The media was removed, and all of the cells were resuspended in a total of 50 ml of media, centrifuged again, and resuspended at a concentration of 5 9 10 7 cells/ml of serum-free media. 5 9 10 6 cells were then aliquoted to one Eppendorf tube per injection site and placed on ice. All procedures then were carried out in a surgical hood in the animal facility. Nude mice were anesthetized with isoflurane. The #4 and #5 mammary gland teats were identified, and the ventral area was cleaned with sterile alcohol pads followed by iodine. A small mid-line incision was made between the #4 teats, and the dermis was separated from the peritoneum. Using a one-half CC syringe with a 27-gauge needle, 100 ll of matrigel was mixed with 5 9 10 6 cells in 100 ll media. A total of 200 ll was injected into the #4 gland near the teat. The incision was closed with a single wound clip. The animals are then placed on their left side, and the area dorsal to the shoulder was cleaned with alcohol and iodine. A 0.72 mg, 60-day slow release pellet (Innovative Research of America, Sarasota, FL, USA) or estrogen tubing with approximately 80 or 300 pg/ml release [22] was placed under the skin, above the shoulder, and the wound was closed with a wound clip. The animal was removed from anesthesia, placed in a warm cage, and monitored until mobile.
Western blot analysis of tumors
Tumors were removed from animals at necropsy and a portion of the tumor was flash frozen in liquid nitrogen. Tumors (50-100 mg) were ground into a fine powder using a mortar and pestle that had been precooled with liquid nitrogen. The sample was lysed in 100 ll lysis buffer per 10 mg of tumor (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM NaF, 1 mM Na 3 VO 4 , 10% glycerol, 1 lm okadaic acid, and Protease inhibitor cocktail, Roche, Basal, Switzerland). A total of 30 lg of whole cell lysate were heated in Laemlli's sample buffer for 5 min, separated by 7.5% SDS-PAGE, transferred to nitrocellulose membrane (Whatman Inc, Sanford, ME, USA), and probed with the following antisera, as indicated; anti-phosphoErk1/2 (Cell Signaling Technology, Danvers, MA, USA), anti-Erk1/2 (Cell Signaling Technology), anti-cyclin D1/2 (Upstate, Charlottesville, NC, USA), and anti-Actin (Sigma, St. Louis, MO, USA). Antisera were as diluted in TBST [tris-buffered saline-0.1% Tween 20 (v/v)] with 5% (w/v) dried milk or 5% (w/v) BSA. Peroxidase-conjugated secondary antisera, goat anti-mouse anti-serum (1:3,000; Amersham Biosciences, Piscataway, NJ, USA), and goat anti-rabbit anti-serum (1:3,000; Amersham Biosciences) were used to detect the respective primary antibodies, and immunoreactive proteins were visualized with ECL chemiluminescence technology (Alpha Innotech, San Leandro, CA, USA). Autoradiographic protein levels were quantified in the linear range of the film by scanning the image using a Canon LicoScan scanner and analyzing with the Scion Image TM software program (Scion Corp., Frederick, MD, USA). Each sample measured was calculated as the ratio of the average area of the phosphorylated protein over the average area of the respective total protein levels. GST pull-down assay Glutathione-S-transferase (GST) pull-down assays were performed as described previously [23] using the plasmid constructs indicated in the figures. The GST-fusion proteins were bound to glutathione-Sepharose 4B beads (Pharmacia). Recombinant proteins (as indicated) were translated in vitro in the presence of [34] S-methionine using the TNT-coupled Reticulocyte Lysate system (Promega), and allowed to bind to the beads loaded with fusion protein in the absence or presence of estradiol as indicated. Proteins were separated by SDS-PAGE and submitted to autoradiography.
Immunoprecipitation
HeLa cells were transiently transfected with expression vectors for AIB1 [19] with equal amounts of pcDNA3.1-WT ERa [24] or K303R ERa plasmids [24] , 24 h later the cells were rapidly starved with phenol-red free media for thrice, each time for 30 min, and then the cells were treated with increasing concentrations of estradiol for 24 h, and then cells were lysed and immunoprecipitated with anti-ER antibody (H184, Santa Cruz Biotech, Santa Cruz, CA, USA), after resolved onto SDS-PAGE and immunoblotted by anti-AIB1 as well as anti-ERa.
Chromatin immunoprecipitation MCF-7 cells stably expressing WT or mutant ERa were treated with estrogen for the indicated times. Following treatment, cells were cross-linked with 1% formaldehyde at 37°C for 10 min and collected into PBS containing protease inhibitors. After centrifugation, cell pellets were resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl at pH 8.1) and sonicated, followed by centrifugation. Supernatants were diluted in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and 20 mM Tris-HCl at pH 8.1). In order to the precleared lysate, antibodies against ER (cocktail of Ab-1, Ab-3, and Ab-10; Neomarkers, Freemont, CA, USA), AIB-1 (N-19; Santa Cruz; Santa Cruz, CA, USA), or p300 (C-20; Santa Cruz) were added, and the reaction was incubated overnight, followed by an addition of 45 ll of protein A/G-sepharose and a further incubation for 1 h. Sepharose beads were then collected and washed sequentially in TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl at pH 8.1, and 150 mM NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl at pH 8.1, and 500 mM NaCl), and buffer III (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl at pH 8.1). Beads were then washed once with TE buffer and extracted with 100 ll of 1% SDS-0.1 M NaHCO 3 . Eluate was heated at 65°C overnight to reverse the formaldehyde cross-linking. DNA fragments were then purified from the eluate of ERa, AIB-1, and p300 immunoprecipitates using a DNA purification kit (QIAquick spin, QIAGEN) and the fragments spanning the ERE sequence of human pS2 promoter were amplified with the primer and protocol described in [15] .
ERa F domain analysis
The DNA fragments encoding the different ERa regions from amino acid 251 to amino acid 557, 566, as well as 554 were generated with PCR using either pcDNA3.1-WT ERa or K303R ERa plasmids as templates, 5
0 BamHI and 5
0
Asp718 sites were designed in the forward and reverse primers, respectively, the PCR fragments were subcloned into pBind vector (Promega Biotech, Madison, WI, USA) through BamHI and Asp718 sites. The U2OS osteosarcoma cells were maintained in phenol-red free MEM supplemented with 5% charcoal-stripped FBS (Hyclone, Logan, UT, USA) for 2 days. One day before transfection, cells were plated in 2 ml media at 2.5 9 10 5 per well in 6-well plates, and then transfected using Fugene 6 reagent (Roche, Indianapolis, IN, USA) following the manufacturer's protocol. Each well was transfected with 1 lg pG5-Luc (Promega Biotech, Madison, WI, USA), 100 ng pCMV-b-gal vector, 10 ng various (as indicated in the figure) pBind-ERa with 100 ng empty vector or TIF2 expression plasmid as indicated. Cells were treated with estrogen (E2, 10 -9 M), or vehicle for an additional 18-24 h, then the cells were washed twice with PBS, harvested into 19 reporter lysis buffer (Promega), and luciferase values as well as b-gal activities were assayed as described [24] . pG5-luciferase activity was normalized by dividing by the b-gal activity to give relative luciferase units. Experiments were performed in triplicate; the data are presented as the average ± SEM, and are representative of three independent experiments. Data is presented as fold induction.
Statistical analysis
Statistical differences among groups were analyzed with student's t-test, Mann-Whitney, or Chi-square analyses where appropriate. Analyses were performed using GraphPad Prism 4 software (GraphPad Software, San Diego, CA, USA).
Results
The K303R ERa mutation renders cells hypersensitive to estrogen in vivo Previously, we have shown that the presence of the K303R ERa mutant renders a cell hypersensitive to low concentrations of estrogen in vitro [5] . We also wanted to determine if lower estrogen concentrations would favor the growth of cells expressing the mutant receptor in vivo in a xenograft tumor model. MCF-7 cells engineered to express WT ERa or K303R-ERa were injected into the #4 gland of nude mice in the presence of 300-400 or 80-100 pg/ml of circulating estrogen. Tumors were measured twice a week, and tumor growth was plotted (Fig. 1a) . The data demonstrate that the mutant receptor-expressing cells exhibited different tumor growth rates at the two different estrogen concentrations. The lower concentration of estrogen supported a more rapid growth rate of mutant ERa-expressing tumors (K303R-ERa vs. WT ERa tumors, P = 0.0466, chi-square), whereas the same cells grew more slowly in the presence of the higher levels of estrogen (P = 0.0018, chi-square). WT ERa-expressing cells did not demonstrate a difference in tumor growth rates at either estrogen concentration (P = 0.4011, chi-square). Thus, while WT ERa cells had similar growth rates in the presence of the two different concentrations of estrogen, as predicted based on their in vitro hypersensitive growth [5] , K303R-ERa tumors grew more rapidly in the presence of lower estrogen concentrations.
Three representative tumors from each group were analyzed by Western blot analysis to determine levels of phosphorylated mitogen activated kinases, ERK1/2 (pMAPK), and cyclin D1 levels as markers of proliferation. Tumors were crushed on liquid nitrogen and lysed as previously described [25] . Western blot analysis demonstrated similar levels of phospho-MAPK levels and cyclin D1 between the WT ERa and K303R-ERa tumors and both estrogen concentrations (Fig. 1b) . This analysis also demonstrates that both estrogen concentrations led to similar levels of activated pMAPK and cyclin D1 proteins.
In order to further analyze the role of the mutant ERa in vivo, WT ERa and K303R-ERa cells were injected into nude mice in the presence of high-dose (300-400 pg/ml) estrogen. When the tumors had reached 150-200 mm 3 , animals were randomized into two groups, to continue high-dose estrogen or switched to no estrogen treatment. WT and mutant-expressing tumors in the high dose groups continued to grow, and all animals had to be killed within 6 months of injection. Similar to our first experiment, there was no difference in tumor growth between WT and mutant ERa-expressing tumors under high E2 concentrations (data not shown). All tumors that were switched to the low dose of estrogen slowly regressed, and (Fig. 2a) and mutant ( Fig. 2b ) ERa; these K d values are well within the range generally reported for estradiol binding to ERa in a number of different assays [26] . Therefore, the hypersensitive phenotype of the K303R mutation is not the result of an obvious change in the affinity of the receptor for estradiol.
Altered coregulator interactions
In order to analyze the mechanisms of estrogen hypersensitivity of the K303R ERa mutant, we examined its interactions with various coregulator proteins known to affect ERa transcription. Previously, we have shown an increased interaction between the mutant ERa and SRC-2 coactivator [5] . Therefore, we further analyzed the protein-protein interactions of WT and mutant ERa with two other SRC coactivator family members using in vitro GST pull-down assays [23] . GST-WT ERa and GST-K303R-ERa fusion constructs containing the hinge-and hormone-binding domains were prepared. SRC family members were synthesized in vitro in the presence of [ 35 S] methionine and then tested for specific hormone-dependent binding to the immobilized GST-ER fusion proteins. Confirming our previous results [5] , SRC-2 bound both receptors in the presence of estradiol (10 -6 M), but not in the absence of estradiol (data not shown). AIB1 also demonstrated increased binding to the mutant ERa at lower concentrations of estrogen when compared with WT ERa (Fig. 3a) . Bound steroid was measured by scintillation counting and specific binding was calculated after subtraction of non-specific binding. Representative Scatchard plots for wild-type (a) and K303R ERa (b) are shown immunoprecipitation (IP) of AIB1 from HeLa cells transiently transfected with WT or mutant ERa, followed by immunoblot analysis for ERa. Figure 3b demonstrates that mutant ERa exhibited increased binding to AIB1 in vivo in the absence (compare lanes 1 and 4) and the presence of 10 -11 and 10 -9 M estrogen (compare lanes 2 and 3 with lanes 5 and 6), respectively. Quantitation of this data is shown in Fig. 3c . Collectively, these data demonstrate that the K303R-ERa mutant receptor binds the SRC 2 and AIB1 coactivators with greater efficiency than WT ERa.
Previous studies have shown that ERa interacts with several members of the preinitiation complex that are required for transcription by RNA polymerase II, as well as with specific receptor coactivators that modulate and integrate transcriptional activity [27] . Since the K303R ERa mutation does not appear to change in hormone-or DNA-binding affinities, we further hypothesized that this mutation might affect its ability to interact with components of the transcriptional machinery. We first assessed if WT and mutant receptors differ in binding to the
GST-WT ERa GST-K303R ERa GST pull-down assays were performed as previously described 13 with the exception of GST-TBP and GST-TFIIB were immobilized on Sepharose beads to capture ERa. Bound receptors were eluted and separated by SDS-PAGE followed by autoradiography. Increasing levels of estradiol were used 1 9 10 preinitiation complex, specifically to the TFIIB and TBP proteins that are involved in the early events of preinitiation complex assembly, and are known to directly interact with ERa [28, 29] . The ability of the two receptors to physically interact in vitro with TFIIB and TBP was evaluated using GST pull-down assays. GST-fusion proteins of TFIIB and TBP were incubated with [34] Slabeled, in vitro translated WT or mutant ERa's in the absence or presence of estradiol. We saw that WT ERa interacts with TFIIB ( Fig. 3d) and TBP (Fig. 3e) in both the absence and the presence of estradiol, as has been previously reported by others [28, 29] . The mutant ER showed that no apparent differences in its interaction with either TFIIB or TBP protein, indicating that the K303R mutation does not alter binding to these proteins of the basal transcriptional machinery, as compared to its altered binding to AIB1 and SRC-2.
Corepressors inhibit WT ERa transactivation but not mutant receptor
In order to analyze the capacity of corepressors to inhibit the transactivation, we tested the ability of NCoR and BRCA1 to affect WT and mutant ERa transactivation. HeLa cells transiently transfected with WT or mutant ERa demonstrated a significant increase in ERE-luciferase activity following estrogen treatment. In the presence of NCoR, cells expressing the WT ERa had a significant reduction in ERa activity (Fig. 4a , compare bars 2 and 4, P = 0.0067, t-test). In contrast, cells expressing the mutant receptor did not show a reduction in ERa transactivation in the presence of NCoR (Fig. 4a , compare bars 6 and 8).
Additionally, the ability of BRCA1 to reduce ERa transactivation demonstrated similar results with the mutant receptor. T47D cells transiently transfected with BRCA1
and WT ERa had a significant reduction in estrogeninduced transactivation (Fig. 4b , compare bars 2 and 4, P = 0.0005, t-test), whereas T47D cells expressing the mutant ERa did not (Fig. 4b , compare bars 6 and 8, P = 0.5, t-test). Collectively, these data demonstrate a reduced ability of corepressors to inhibit estrogen-mediated activity of the mutant ERa.
ERa promoter dynamics
Previous reports have demonstrated that ERa and its cofactors cycle on and off of the promoter in a dynamic manner [14] [15] [16] . GST pull-down experiments demonstrated increased binding of ERa and the SRC family of coactivators to the mutant; therefore, we wanted to determine if cofactor dymanics of the pS2 promoter were altered in the presence of the K303R ERa mutation. CHIP analysis was performed for ERa, SRC-3, and p300 binding on the PS2 promoter following estrogen treatment. MCF-7 cells stably expressing the WT or K303R-ERa were subjected to CHIP analysis following serum starvation and estrogen treatment for the indicated timepoints. WT ERa-expressing cells demonstrated a cycle time of approximately 120 min, with delineated two cycles in a 300-min assay (Fig. 5a ). In contrast, K303R ERa expressing cells had an initial increase in ERa on the pS2 promoter, but did not demonstrate an ''off'' cycle at 120 min (Fig. 5a ). Additionally, this initial ''on'' cycle of the K303R ERa was reduced when compared to WT ERa expressing cells. Further analysis of the dynamics with the K303R mutant receptor revealed that despite the lack of an ''off'' cycle, the second ''on'' cycle occurred at a similar timepoint as WT ERa, and this second cycle had higher amplitude, with a longer residence time on the pS2 promoter when compared with WT ERa (Fig. 5a ). Collectively, these data demonstrate
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Transactivation Assays Analysis of SRC-3 occupancy on the pS2 promoter in WT ERa-expressing cells demonstrated an initial cycle with a peak at 60 min followed by a second peak at 120 min (Fig. 5b) . Additionally, this second cycle had increased amplitude and a longer ''on'' time compared with the first peak (Fig. 5b) . Cells expressing the K303R ERa mutant demonstrated maximal interaction with the pS2 promoter at 120 min (Fig. 5b) . In contrast to the WT ERaexpressing cells, a suggestion of cycling was observed, but the values never reached basal levels and the amount of mutant ERa present on the promoter was always elevated compared to WT ERa expressing cells (Fig. 5b) . In order to confirm that the presence of the K303R ERa protein altered coactivator dynamics, the dynamics of p300 in the presence of WT ERa or mutant ERa were also analyzed. In the presence of WT receptor p300 protein occupancy on the pS2 promoter initially peaked at 30 min followed by a return to basal levels, and then a second peak at 150 min post-estrogen stimulation (Fig. 5c) . K303R ERa expressing cells demonstrated a longer cycle time with an initial peak at 90 min, followed by a return to basal levels (Fig. 5c) . The second peak in the K303R ERa expressing cells had higher amplitude when compared to the first peak. When compared with WT ERa, this second peak occurred later and was also elevated (Fig. 5c) . Collectively, these data demonstrate that in the presence of the mutant K303R ERa cells display increased coactivator interactions on the pS2 promoter.
The K303R ERa mutation does not create a new coregulator binding site
We observed an increased interaction between the SRC family of coactivators and the mutant receptor. However, the reported interaction site for TIF-2 on ERa is residues 539-544 [18] . In order to determine if the K303R ERa mutation created a new binding site within the hinge domain, we performed GST pull-down experiments with a number of truncated ERa constructs. As expected, the ERa fragment-containing residues 263-595 encompassing the hinge-and hormone-binding domain bound TIF-2 in the presence of estrogen (Fig. 6, lane 2 vs. lane 3) . When only the hinge domain was used, no binding was observed for either the WT or the mutant receptor (Fig. 6, lanes 4-7) , thus demonstrating that the increased binding of ERa to TIF-2 was not due to the creation of a new TIF-2 binding site.
The ERa F domain plays an important role in ERa regulation
It has previously been shown that regions within the F domain of ERa, in part, serve to modulate its transcriptional activity, including the effects of coactivators, agonist, and antagonist [30] [31] [32] Fig. 5 Mutant ERa displays altered dynamics on the promoter. Chromatin immunoprecipitation was performed on the pS2 for ERa (a), SRC-3 (b), and p300 (c) in WT ERa or K303R ERa cells, as indicated. Cells were treated with estrogen for the indicated timepoints, lysed, protein was immunoprecipitated, and the relevant sequence from the pS2 promoter was amplified by semi-quantitative PCR as described in ''Materials and methods''. Relative levels were quantitated and graphed equilibrium of ERa toward a more active state in the absence of ligand [33] . Recently, Koide et al. have shown that residues immediately distal to Q580 play an important role in the regulatory function of the F domain [34] , and TIF-2 binds to ERa within the F domain. Therefore, we wanted to determine if the modulatory function of the F domain was altered in the presence of the K303R mutation. Transactivation assays were analyzed in the presence or absence of exogenous TIF-2 to determine the ability of TIF-2 to coactivate transactivation of serial deletion mutants of the F domain. GAL4-DBD fusion constructs of WT ERa and K303R ERa fragments were examined using a GAL4 binding site, and a TATA promoter-luciferase reporter in the presence of estrogen. ERa constructs containing the amino acids 251-595 (hinge and regions E-F), 251-577 (hinge, region E and F truncation), 251-566 (hinge, region E and F truncation), and 251-554 (hinge and region E) were used.
As expected, both the WT and mutant ERa 251-595 constructs demonstrated estrogen-induced coactivation that was increased in the presence of TIF-2, thus indicating that TIF-2 can serve to effectively coactivate ERa activity in this model system. Additionally, the mutant-containing construct demonstrated increased activity in the both presence and absence of TIF-2 when compared with WT ERa. When the WT ERa construct was truncated at amino acid 577, the basal level of activation was increased to a level similar to the mutant receptor. Furthermore, TIF-2 coexpression only resulted in a small increase in coactivation of WT ERa. Analysis of the deletion constructs WT ERa 251-566 and 251-554 demonstrated that in the absence of TIF-2, transactivation was increased above the full-length, but to similar levels as to the 577 truncation. While the 577 truncation only resulted in a small increase in TIF-2-induced coactivation, the 566 and 554 truncations allowed for a greater coactivation by TIF-2. In contrast, the deletion constructs 251-577 and 251-566 containing the K303R mutation all demonstrated similar results as the full-length K303R construct. However, the K303R 251-554 deletion construct demonstrated a small increase in transactivation when compared with the additional three constructs analyzed.
Collectively, these data demonstrate that amino acids 577-595 contain an important regulatory domain for estrogeninduced transactivation of WT ERa. Additionally, while all constructs demonstrated TIF-2-induced coactivation, amino acids 566-595 contain a regulatory domain that plays a role in the levels of coactivation by TIF-2. Since the K303R mutant ERa construct was only marginally affected by deletion of these regulatory domains, it suggests that the presence of this K303R mutation within the hinge domain alters the ability of the F domain to regulate ERa transactivation. These data suggest that the hinge domain plays an important role in regulating the ability of the F domain to modulate ERa transactivation.
Discussion
As we have demonstrated previously, the mutant K303R ERa is a better substrate for phosphorylation by PKA at S305 [10] , and S305 has been shown to be a PAK-1 phosphorylation site [9] . Additionally, K302/K303 is an important acetylation site, and is regulated, in part, by the phosphorylation status of S305 [10] . Furthermore, the K303 site can be further regulated by sumoylation, thereby influencing WT ERa transactivation [35] . It is clear that this lysine is involved in sumoylation, acetylation, and regulation of S305 phosphorylation, thus it is a major site of ERa posttranslational modifications, of which, the consequences can be seen in the altered coregulator interactions. While cofactors such as SRC-1, 2, and 3, demonstrated increased binding, TBP and TFIIB did not demonstrate altered binding. Additionally, transactivation analyses have previously shown that MTA-1 can repress the activity of both WT and mutant ERa [12] , and MTA-2 can only suppress the activity of WT ERa and not the mutant ERa [13] . It is important to reiterate that not all cofactors tested were affected by the K303R ERa mutation, thus demonstrating specific cofactor regulation rather than affecting the global signaling of the protein. Here, we show that both BRCA-1 and NCoR have the ability to repress the activity of WT ERa, but not the mutant ERa (Fig. 6) . Furthermore, corepressors demonstrated differences in activity between the WT and mutant ERa proteins. Collectively, these data demonstrate that the 303 lysine is an important site of post-translational regulation and its mutation to arginine can significantly alter the protein's interactions with coregulatory proteins. The F domain of ERa has an important role in the regulation of ERa ligand responses. While many studies have analyzed the F domain in response to various agonist and antagonist ligands, the results are not always consistent. Recently, Koide et al. have published results demonstrating that deletion of the entire F domain from full-length ERa reduced the ability of ERa to increase transactivation in response to estrogen [32] . Previous results from the same laboratory have shown that deletion of the F domain did not affect estrogen-induced transactivation of ERa [36] , thus demonstrating complex regulation by the F domain. The previous two studies analyzed the full-length (minus the F domain) receptor in HeLa cells. An additional study utilizing amino-terminal truncated forms of ERa in a yeast assay demonstrated that the F domain was inhibitory to estrogeninduced ERa transactivation [37] . While the recent studies by Koide et al. demonstrated reduced transactivation in F domain truncation mutants, they further narrowed the important region to amino acid residues 579-584 [32] . This is interesting because our studies reported here, also demonstrate that amino acids 577-595, and 577-566, play important roles in the regulation of WT ERa transactivation. First, deletion of the amino acids 577-595 increased estrogen-induced transactivation, but did not have a great impact on ability of the coactivator TIF-2 of affect transactivation. In contrast, the further deletion of residues 566-595 significantly increased the ability of TIF-2 to coactivate WT ERa transactivation. While previous studies using fulllength ERa have demonstrated no effect [36] or reduced [32] ERa transactivation when the F domain was deleted, our studies herein demonstrate that the F domain acts to inhibit estrogen-induced transactivation and TIF-2 coactivation of ERa. Our studies utilized an amino truncated form of ERa beginning at amino acid 251, thus removing the ligandindependent AF-1 domain to allow us to study the F domain functions in the absence of inherent ligand-independent transactivation. Our studies demonstrating an AF-2 inhibitory region within the F domain are in agreement with previously published results showing that in the absence of the AF-1 region, the F domain reduces estrogen-induced transactivation [37] . Thus, the F domain may act in concert with the AF-1 region, to regulate the ligand-dependent AF-2 transactivation.
While the F domain contains a regulatory region, it appears that the K303R ERa mutation results in a loss of this regulation. In Fig. 7 , serial truncations of the F domain only resulted in an increased ERa transactivation when the full F domain was deleted, the increase was modest. In contrast, all truncated constructs analyzed led to an altered transactivation by WT ERa. Collectively, these data demonstrate that the F domain has important roles for both ligand and coactivator-induced transactivation of WT ERa. Additionally, as the K303R ERa only demonstrated a marginal response to F domain deletion, and deletion of the F domain in WT ERa caused the WT ERa to behave like K303R ERa, these data suggest that the regulatory units within the F domain may play a role in the hypersensitive phenotype of K303R ERa expressing cells. Studies evaluating ERa and coactivators on promoters of target genes have shown that these proteins cycle ''on'' and ''off'' promoters, and estrogen treatment leads to elongated promoter cycling and an increased amplitudes of each cycle [14] . Additionally, when cells were treated with the proteosome inhibitor MG-132 to reduce regulated turnover, promoter occupancy was reduced, and the ''off'' phase of the cycle was significantly elongated, thus demonstrating that increased promoter activity is associated with increased amplitude and elongated cycles, where as reduced activity is associated with an elongated ''off'' cycle and reduced amplitudes. Based on this data, we would expect the hypersensitive K303R ERa to demonstrate an elongated cycle time and increased amplitude. Here, we demonstrate that WT ERa expressing cells demonstrated similar cycling dynamics as those previously reported. However, the K303R ERa expressing cells demonstrated altered dynamics with the amplitude of the initial cycle is reduced whereas the amplitude of the second cycle is increased. Furthermore, two coactivators, AIB1, and p300 also demonstrated altered dynamics with increased amplitude and elongated cycle times. Thus, these coactivators confirm the changes observed in promoter dynamics of the K303R ERa. The increased amplitudes and elongated ''on'' phase of the cycles alone would suggest increased signaling by the K303R mutant receptor, combined with the increased interactions with coactivator proteins and the hypersensitive phenotype previously reported.
Tumors grown as xenografts in nude mice displayed an increased ability of K303R ERa cells to grow in the presence of low estrogen concentrations. Additionally, when estrogen was withdrawn, 50% of K303R ERa experimental tumors displayed estrogen-independence in approximately 1-year time. In contrast, no WT ERaexpressing cells gained estrogen independence during this period. In vitro, when MCF-7 cells are grown in the absence of any estrogen stimulation, estrogen independence eventually develops and the cells will also form tumors in the presence of low estrogen concentrations [4] . In contrast to this data, only the mutant ERa-expressing cells demonstrated an ability to develop estrogen independence in vivo. Cyclin D1 and phospho-MAPK were analyzed as markers of proliferation in the wild-type versus K303R ERa cells. Our initial analyses did not reveal any differences in these two proteins. Thus, thorough study of the potentially activated mechanisms of tumor growth is warranted, and will require a more detailed analysis that is beyond the scope of this article.
Here, we have demonstrated an important role for the K303R ERa mutation in human breast cancer. The data would suggest that this particular mutation would demonstrate a more important role in the development and/ or recurrence of breast cancer in an estrogen-independent manner. Indeed, our recently published in vitro results suggest that the mutation could play a role in resistance to aromatase inhibitors [38] . These data also demonstrate that the K303R ERa has increased transcriptional activation and a loss of the ''normal'' F domain-mediated regulatory mechanisms inherent in the WT ERa; it would not be surprising if this mutant receptor also plays an important role in the development and progression of estrogen responsive breast cancer.
